Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...

Full description

Bibliographic Details
Main Authors: Laura Tookman, Jonathan Krell, Baleseng Nkolobe, Laura Burley, Iain A. McNeish
Format: Article
Language:English
Published: SAGE Publishing 2020-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920921980

Similar Items